Therapeutic proteasome inhibition in experimental acute pancreatitis

Tamás Letoha, Liliána Z Fehér, László Pecze, Csaba Somlai, Ilona Varga, József Kaszaki, Gábor Tóth, Csaba Vizler, László Tiszlavicz, Tamás Takács

Abstract

AIM: To establish the therapeutic potential of proteasome inhibition, we examined the therapeutic effects of MG132 (Z-Leu-Leu-Leu-aldehyde) in an experimental model of acute pancreatitis.

METHODS: Pancreatitis was induced in rats by two hourly intraperitoneal (ip) injections of cholecystokinin octapeptide (CCK; 2 × 100 μg/kg) and the proteasome inhibitor MG132 (10 mg/kg ip) was administered 30 min after the second CCK injection. Animals were sacrificed 4 h after the first injection of CCK.

RESULTS: Administering the proteasome inhibitor MG132 (at a dose of 10 mg/kg, ip) 90 min after the onset of pancreatic inflammation induced the expression of cell-protective 72 kDa heat shock protein (HSP72) and decreased DNA-binding of nuclear factor-κB (NF-κB). Furthermore MG132 treatment resulted in milder inflammatory response and cellular damage, as revealed by improved laboratory and histological parameters of pancreatitis and associated oxidative stress.

CONCLUSION: Our findings suggest that proteasome inhibition might be beneficial not only for the prevention, but also for the therapy of acute pancreatitis.

Key words: Acute pancreatitis; Cholecystokinin octapeptide; Proteasome inhibition; Nuclear factor-κB; Heat shock proteins

INTRODUCTION

Proteasome inhibition is an emerging strategy to attenuate the inflammatory response.[2,9,10] Inhibiting the proteasome blocks nuclear factor-κB (NF-κB) activation by detaining proteolysis of its inhibitory subunit, the 1κB. Preventing NF-κB activation then decreases NF-κB dependent proinflammatory gene expression, resulting in reduced inflammatory response. However studies also reveal that NF-κB, one of the major initiators of pro-inflammatory pathways, has anti-inflammatory roles in the resolution of inflammation. Thus inhibiting NF-κB during the resolution of inflammation has been shown to protract the inflammatory response in vivo.[10]

Acute pancreatitis is a severe inflammatory disease characterized by intrapancreatic activation of digestive enzyme zymogens that leads to acinar cell injury and subsequent inflammatory response.[2,9] The inflammatory response is first localized only to the pancreas, but due to the release of inflammatory mediators, later overspreads and becomes systematic affecting other organs including the lung and kidney. This exacerbation of pancreatitis results in multiple organ failure and systemic inflammatory response syndrome that is responsible for the mortality of acute pancreatitis. There have been many experimental attempts for the treatment of acute pancreatitis, however most failed to succeed in the clinics.[2,9] This might stem from the fact that many studies aim to examine only the prophylactic effects of compounds. One thing is clear however, the therapeutic potential of a compound in acute pancreatitis can only be established if it is given after onset of the disease.[2,9] In our previous study the peptide aldehyde proteasome inhibitor MG132 prevented the development of pancreatic inflammation when administered
before the induction of the disease\textsuperscript{[10]}. In order to estimate the clinical potential of proteasome inhibition, we also had to examine the therapeutic effects of the compound administered after the onset of pancreatitis. Given the NF-κB inhibitory effects of MG132, it was also crucial to determine whether NF-κB inhibition with MG132 after the onset of pancreatic inflammation might worsen or ameliorate pancreatitis. The following paper will summarize the observed effects of therapeutic administration of MG132 in this experimental model of acute pancreatitis and suggest that proteasome inhibition might be beneficial for the therapy of the disease.

**MATERIALS AND METHODS**

**Experimental protocol**

For the in vivo studies male Wistar rats (provided by the Animal Center of the University of Szeged) weighing 250-300 g were used. The animals were kept at constant room temperature with a 12-h light-dark cycle, and were allowed free access to water and standard laboratory chow (Biofarm, Zagyvaszánto, Hungary). Animal experiments performed in this study were approved by the Animal Care Committee of the University and complied with the European Communities Council Directive of 24 November 1986 (86/609/EEC). In each experimental group eight rats were used ($n = 8$). Acute pancreatitis was induced by injecting 100 μg/kg of CCK (synthesized in the Department of Medical Chemistry, Szeged, Hungary as described by Penke et al\textsuperscript{[11]}; dissolved in physiological saline) twice with an interval of 1 h (Figure 1).

Ninety minutes after the first CCK injection, the animals were injected intraperitoneally (ip) either with 10 mg/kg of MG132 [Z-Leu-Leu-Leu-aldehyde; Sigma; dissolved in 0.25 mL dimethyl sulfoxide (DMSO)] or with an equal volume of DMSO (Sigma) alone. Controls received physiological saline (PS) and DMSO in the same manner. Four hours after the first CCK or saline injections, the animals were anesthetized (with pentobarbital sodium 50 mg/kg, ip) and killed previously with pentobarbital sodium 10 mg/kg, ip.

**Procedures**

**Nuclear protein extraction:** Nuclear protein extracts were prepared as described previously\textsuperscript{[12]}.  

**Electrophoretic mobility shift assay (EMSA) of NF-κB:** EMSA of NF-κB was carried out as described previously\textsuperscript{[11,12]}.

**Western blotting:** Western blot analysis of pancreatic heat shock protein 72 (HSP72) and IkBα was performed as described by Rakonczay et al\textsuperscript{[11,12,13]}. α-tubulin was used as a loading control.

**Serum amylase activity assay:** The pancreatic weight/body weight ratio was utilized to evaluate the degree of pancreatic edema. To measure the serum amylase activities, all blood samples were centrifuged at 2500 $\times$ g for 20 min. The serum levels of amylase were determined by a colorimetric kinetic method (Dialab, Vienna, Austria).

**Pancreatic tumor necrosis factor-α and interleukin-6 levels:** Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) concentrations were measured in the pancreatic cytosolic fractions with ELISA kits (Bender Medsystems, Vienna, Austria) according to the manufacturers’ instructions.

**Pancreatic and lung myeloperoxidase activity:** Pancreatic and lung myeloperoxidase (MPO) activity, as a marker of tissue leukocyte infiltration, was assessed by the method of Kuebler et al\textsuperscript{[14]}.  

**Real time quantitative polymerase chain reaction (RT-qPCR):** RT-qPCR was performed on a RotorGene 3000 instrument (Corbett Research, Australia) with gene-specific primers (designed with the software PrimerExpress, Applied Biosystems, USA) and SYBRGreen I protocol as described previously\textsuperscript{[15,16]}. Relative expression ratios were normalized to cyclophilin and calculated with the Pfaffl method\textsuperscript{[17]}. The PCR primers used were as follows: cyclophilin, forward primer, 5'-TCTCTTCAAGGGACGAAGCG-3', reverse primer, 5'-TGGAATTCGCTGAGCG-3'; proteasome-associated protein (PAP), forward primer, 5'-ACTTCCTGCAC-3', reverse primer, 5'-ATGACAGGGCATAGCAGTAGG-3'.

**Lipid peroxidation, reduced glutathione levels and activities of superoxide dismutase and catalase:** Lipid peroxides may undergo metal- or enzyme-catalyzed decomposition to form multiple products, including malondialdehyde (MDA). Pancreatic MDA levels were measured according to the MDA/TBA-high performance liquid chromatographic (HPLC) method of Wong et al\textsuperscript{[18]} and were corrected for the protein content of the pancreas. Reduced glutathione (GSH) levels were determined spectrophotometrically with Ellman’s reagent\textsuperscript{[19]}. Pancreatic total superoxide dismutase (SOD) activity was determined on the basis of the inhibition of epinephrine-adrenochrome autoxidation\textsuperscript{[19]}.

---

**Figure 1** Experimental protocol of acute pancreatitis.
The total pancreas weight/body weight ratio and serum amylase activity

Injecting $2 \times 10^6 \mu g/kg$ body weight of CCK resulted in elevated serum amylase levels and pancreas weight/body weight ratio, signs of acinar injury and pancreatic inflammation\([21,22]\). These actions of CCK were interfered by MG132 treatment (Figure 2A).

Intrapancreatic proinflammatory cytokine levels

Inflammatory mediators, like TNF and IL-6 couple the local pancreatic inflammation with systemic complications such as pancreatitis-associated lung and renal-injury\([23,24]\). In our study CCK significantly increased the expression of TNF and IL-6 in the pancreas compared to controls. MG132 treatment reduced intrapancreatic TNF and IL-6 levels (although, compared to Group CCK, the effect of MG132 on pancreatic TNF levels were not statistically significant, as shown in Figure 2B).

Pancreatic and lung myeloperoxidase activity

Neutrophils produce an enzyme called myeloperoxidase that can be used to identify the amount of neutrophils infiltrating a tissue after inflammation\([25]\). CCK hyper-stimulation increased MPO activity in both the pancreas and lung, reflecting the elevated levels of neutrophil infiltration within these organs. Proteasome inhibition with MG132 decreased MPO activity in the lung and pancreas (Figure 2C).

Expression of pancreatitis-associated protein

Pancreatitis-associated protein (PAP), the acute-phase protein of the pancreas, is overexpressed in acute pancreatitis\([26]\). Supramaximal CCK doses significantly increased the expression of PAP mRNA. MG132 treatment could interfere markedly with this effect of CCK (Figure 3).

Parameters of oxidative stress

Two hourly injections of CCK induced pancreatic inflammation and underlying oxidative stress. Thus, the ferric reducing ability of plasma (FRAP), as an index of total antioxidant capacity was reduced four hours after the induction of pancreatitis. Moreover CCK stimulation depleted SOD activity and GSH, the two important antioxidant defense systems and increased malondialdehyde content (the marker of lipid peroxidation) in the pancreas. MG132 treatment inhibited the production of reactive oxygen species due to CCK hyperstimulation, as judged by the improvements of above mentioned laboratory parameters of antioxidant power and oxidative stress (Figure 4A and B).
Pancreatic heat shock protein 72 (HSP72) levels

Induction of heat-shock proteins is a useful tool to increase cellular tolerance against stress\(^{27,28}\). Injections of CCK elevated the levels of pancreatic HSP72 four hours after the first CCK injection. MG132, the well-known inducer of heat-shock proteins, further increased the expression of HSP72 in the pancreas (Figure 5A and B).

Pancreatic NF-κB activation

In the pancreas, supramaximal doses of CCK triggered the degradation of IκB\(\alpha\) and subsequent activation of NF-κB, based on Western blots and EMSAs carried out on pancreatic samples of animals involved in our study. Inhibiting the proteasome decreased IκB\(\alpha\) degradation (Figure 5A and C) and DNA-binding of NF-κB (Figure 6A and B) (The effects of MG132 on IκB\(\alpha\) degradation were not significant statistically).

Histological findings

CCK hyperstimulation resulted in cytoplasmic vacuolization and death of acinar cells, edema formation, and infiltration of inflammatory cells in the pancreas samples of CCK-treated animals (Figure 7A). Treating the animals with the proteasome inhibitor MG132 inhibited the cellular damage and inflammatory response due to CCK, as reflected by milder histopathological changes in the pancreas (Figure 7B).
Effect of $k$, Gilroy DW, Colville-Nash PR, Willoughby

Intrapancreatic activation of digestive enzyme zymogens can be prevented by the inhibition of lysosomal hydrolyses like cathepsin B [29-31]. NF-$k$B activation can also be prevented by inhibiting the proteasome and other proteases (like calpains) that degrade the inhibitory 1kB subunit [32-35]. MG132 is a peptide aldehyde proteasome inhibitor with a broad inhibitory range, showing selectivity towards both serine and cysteine proteases including cathepsins and calpains [1,36]. To make it more complex, MG132 has the ability to induce heat shock proteins (including HSP72), which increases cellular tolerance to stress [37,38].

In our earlier study we have shown that pretreatment of rats with MG132 protected against acute pancreatitis by preventing NF-$k$B activation and inducing the expression of HSP72 [29]. However the therapeutic value of prophylactic treatment in acute pancreatitis is indeed very doubtful. In order to validate the therapeutic potential of proteasome inhibition in pancreatitis, we also tested the effects of therapeutic administration of MG132 in an experimental model of the disease. Pancreatitis was induced by two hourly injections of the cholecystokinin octapeptide (CCK).

DISCUSSION

Acute pancreatitis is a severe inflammatory disease triggered by abnormal activation of intrapancreatic proteases and enhanced transcriptional activity of stress-responsive transcriptional factors like NF-$k$B [1-3]. Intrapancreatic activation of digestive enzyme zymogens can be prevented by the inhibition of lysosomal hydrolyses like cathepsin B [29-31]. NF-$k$B activation can also be prevented by inhibiting the proteasome and other proteases (like calpains) that degrade the inhibitory 1kB subunit [32-35]. MG132 is a peptide aldehyde proteasome inhibitor with a broad inhibitory range, showing selectivity towards both serine and cysteine proteases including cathepsins and calpains [1,36]. To make it more complex, MG132 has the ability to induce heat shock proteins (including HSP72), which increases cellular tolerance to stress [37,38].

In our earlier study we have shown that pretreatment of rats with MG132 protected against acute pancreatitis by preventing NF-$k$B activation and inducing the expression of HSP72 [29]. However the therapeutic value of prophylactic treatment in acute pancreatitis is indeed very doubtful. In order to validate the therapeutic potential of proteasome inhibition in pancreatitis, we also tested the effects of therapeutic administration of MG132 in an experimental model of the disease. Pancreatitis was induced by two hourly injections of the cholecystokinin octapeptide (CCK). In this model of the disease, CCK hyperstimulation resulted in pancreatic inflammation characterized by intracellular activation of digestive enzymes and elevation of their serum levels, cytoplasmic vacuolization and death of acinar cells, edema formation, infiltration of inflammatory cells and oxidative stress. Thus severity of pancreatitis could be very accurately detected by monitoring the laboratory parameters of the disease.

Administering MG132 90 min after the onset of pancreatic inflammation could still ameliorate the severity of the disease. So MG132 treatment could decrease cellular damage, inflammation and subsequent oxidative stress associated with pancreatitis. These beneficial effects of MG132 can be explained by its ability to induce the expression of HSP72 that protects cells against stressful conditions. MG132 also decreased the transcriptional activity of NF-$k$B. NF-$k$B, however, has a dual role in inflammatory diseases, because besides triggering proinflammatory cellular events during first phase of the inflammatory response, it has also anti-inflammatory role during the resolution of inflammation [39]. In CCK-induced pancreatitis, NF-$k$B activation peaks in the first phase of the disease [40]. Since in MG132 treatment had more pronounced effects on HSP72 than on NF-$k$B, thus it is likely that in our case the induction of heat shock proteins made larger contribution to the observed beneficial effects of MG132 in acute pancreatitis than NF-$k$B inhibition.

Our observation that MG132 could ameliorate the severity of acute pancreatitis when administered 90 min after the induction of the disease is indeed very promising. Considering this, we have to note that although supramaximally stimulating doses of CCK cause the inflammatory response that underlies many of the features of human pancreatitis, still CCK-induced pancreatitis is a mild model of the disease [41]. Thus MG132 and other proteasome inhibitors should be further tested in other, more severe models of pancreatitis in order to accurately determine the clinical potential of proteasome inhibition for the treatment of acute pancreatitis.

REFERENCES

1 Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 2003; 81: 235-245
2 Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby
DA. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 2001; 7: 1291-1297
3 Weber CK, Adler G. From acinar cell damage to systemic inflammatory response: current concepts in pancreatitis. Pancreatology 2001; 1: 356-362
4 Algül H, Tando Y, Schneider G, Weidenbach H, Adler G, Schmid RM. Acute experimental pancreatitis and NF-kappaB/Rel activation. Pancreatology 2002; 2: 503-509
5 Bhatia M, Wong FL, Cao Y, Lau HY, Huang J, Puneet P, Chevali L. Pathophysiology of acute pancreatitis. Pancreatology 2005; 5: 132-144
6 Weber CK, Adler G. Acute pancreatitis. Curr Opin Gastroenterol 2003; 19: 447-450
7 Adler G. Has the biology and treatment of pancreatic diseases evolved? Best Pract Res Clin Gastroenterol 2004; 18 Suppl: 83-90
8 Bhatia M, Neoptolemos JP, Slavin J. Inflammatory mediators as therapeutic targets in acute pancreatitis. Curr Opin Investig Drugs 2001; 2: 496-501
9 Bhatia M. Inflammatory response on the pancreatic acinar cell injury. Scand J Surg 2005; 94: 97-102
10 Letoha T, Somlai C, Takács T, Szabolcs A, Rakonczay Z, Jármay K, Szalontai T, Varga I, Kaszaki J, Boros I, Duda E, Hackler L, Kurucz I, Penke B. The proteasome inhibitor MG132 protects against acute pancreatitis. Free Radic Biol Med 2005; 39: 1142-1151
11 Penke B, Hajnal F, Lonovics J, Holzinger G, Kadar T, Telegedy G, Rivier J. Synthesis of potent hepatoprotective analogues of cholecystokinin. J Med Chem 1984; 27: 845-849
12 Rakonczay Z, Duda E, Kaszaki J, Iványi B, Boros I, Lonovics J, Takács T. The anti-inflammatory effect of methylprednisolone occurs down-stream of nuclear factor-kappaB DNA binding in acute pancreatitis. Eur J Pharmacol 2003; 464: 217-227
13 Letoha T, Somlai C, Takács T, Szabolcs A, Jarmay K, Jármay K, Szalontai T, Varga I, Kaszaki J, Boros I, Duda E, Hackler L, Kurucz I, Penke B. The proteasome inhibitor MG132 protects against acute pancreatitis. Free Radic Biol Med 2005; 39: 1142-1151
14 Penke B, Hajnal F, Lonovics J, Holzinger G, Kadar T, Telegedy G, Rivier J. Synthesis of potent hepatoprotective analogues of cholecystokinin. J Med Chem 1984; 27: 845-849
15 Rakonczay Z, Iványi B, Varga I, Boros I, Jednákovits A, Németh I, Lonovics J, Takács T. Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats. Free Radic Biol Med 2002; 32: 1283-1293
16 Kuebler WM, Abeles C, Schuerer L, Goetz AE. Measurement of neutrophil content in brain and lung tissue by a modified myeloperoxidase assay. Int J Microcirc Clin Exp 1996; 16: 89-97
17 Nagy ZB, Kelemen JZ, Fehér LZ, Zvara A, Juhász K, Puskás LG. Real-time polymerase chain reaction-based exponential sample amplification for microarray gene expression profiling. Anal Biochem 2005; 337: 76-83
18 Wong SH, Knight JA, Hopfer SM, Zaharia O, Leach CN, Sunderman FW. Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin Chem 1987; 33: 214-220
19 Sledak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulphydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968; 25: 192-205
20 Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170-3175
21 Benzie IF, Strain JF. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 1996; 239: 70-76
22 Ranson JH. Diagnostic standards for acute pancreatitis. World J Surg 1997; 21: 136-142
23 Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol 2002; 97: 1309-1318
24 Bhatia M, Brady M, Shokouhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol 2000; 190: 117-125
25 Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg 2002; 9: 401-410
26 Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77: 598-625
27 Savković V, Gaiser S, Jovanna JL, Bödeker H. The stress response of the exocrine pancreas. Dig Dis 2004; 22: 239-246
28 Rakonczay Z, Takács T, Boros I, Lonovics J. Heat shock proteins and the pancreas. J Cell Physiol 2003; 195: 383-391
29 Schafer C, Williams JA. Stress kinases and heat shock proteins in the pancreas: possible roles in normal function and disease. J Gastroenterol 2000; 35: 1-9
30 Halangk W, Lerch MM. Early events in acute pancreatitis. Clin Lab Med 2005; 25: 1-15
31 Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R, Li M, Sato K, Saluja AK, Steer ML, Goldberg AL, Simons M. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest 2000; 106: 439-448
32 Zaninovic V, Gukovskaya AS, Gukovski I, Mouria M, Pandol SJ. Cerulatin upregulates ICAM-1 in pancreatic acinar cells, which mediates neutrophil adhesion to these cells. Am J Physiol Gastrointest Liver Physiol 2000; 279: G794-G800
33 Halangk W, Lerch MM. Early events in acute pancreatitis. Clin Lab Med 2005; 25: 1-15
34 Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998; 8: 397-403
35 Bush KT, Goldberg AL, Ngam SK. Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J Biol Chem 1997; 272: 9086-9092
36 Lee DH, Goldberg AL. Proteasome inhibitors cause induction of heat shock proteins and trehalose, which together confer thermotolerance in Saccharomyces cerevisiae. Mol Cell Biol 1998; 18: 30-38
37 Gukovskaya AS, Blihnman TA, Zaninovic V, Pandol SJ. Early NF-kappaB activation is associated with hormone-induced pancreatitis. Am J Physiol 1998; 275: G1402-G1414
38 Lerch MM, Adler G. Experimental animal models of acute pancreatitis. Int J Pancreatol 1994; 15: 159-170

S-Editor Zhu LH I-Editor Alpini GD E-Editor Li JL

www.wignet.com